HER2 Dual ISH DNA Probe Cocktail
Ventana Medical Systems, Inc. · Decision date May 15, 2026
What did the FDA approve?
FDA records P190031/S015 as a supplement to PMA P190031, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 15, 2026.
FDA approval order statement
Approval to include HER2 Dual ISH DNA Probe Cocktail as a companion diagnostic indication for the determination of HER2 gene amplification status in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- May 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190031/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Ventana Medical Systems, Inc.
- Product code
- NYQ
- Decision code
- APPR
- Decision date
- May 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer.
- Applicant
- Ventana Medical Systems, Inc.
- Product code
- NYQ
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190031/S015 received
Application receipt date recorded by FDA.
P190031/S014 · Related supplement
HER2 Dual ISH DNA Probe Cocktail
P190031/S015 · FDA decision
Normal 180 Day Track
P190031/S016 · Related supplement
VENTANA HER2 Dual ISH DNA Probe Cocktail
Timeline entries are records held by MedtechLedger for P190031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HER2 Dual ISH DNA Probe CocktailP190031/S014 | Ventana Medical Systems, Inc. | PMA supplement | Dec 15, 2025 | FDA |
VENTANA HER2 Dual ISH DNA Probe CocktailP190031/S016 | Ventana Medical Systems, Inc. | PMA supplement | Aug 25, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P190031/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
